Voz

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Voz

Property Description
Active ingredient Levofloxacin
Form Tablets, IV Solution, Topical Solutions
Pharmacological class Fluoroquinolone Antibiotic
Common purpose Eradicating bacterial infections
Origin Synthetic

The medicine Voz is the brand name for the active substance Levofloxacin, which is a powerful, synthetic, single-ingredient antibacterial agent used to eliminate bacterial infections. Its core identity is rooted in its classification as a third-generation fluoroquinolone antibiotic, a class clinically recognized for its efficacy against a broad range of bacterial threats. Levofloxacin acts by preventing bacterial cells from dividing and repairing themselves.


What Type of Antibiotic is Voz? (Classification and Origin)

Voz is classified as a synthetic broad-spectrum antibiotic belonging to the fluoroquinolone group, meaning it is entirely manufactured through chemical synthesis rather than being derived from natural sources. The active compound, Levofloxacin, is defined as the highly purified S-(-)-isomer of its precursor Ofloxacin, an optimized chemical structure that provides a consistent and potent therapeutic action. This selective synthesis process ensures a highly targeted and predictable effect against susceptible bacteria. As a prescription-only (Rx) medication, Voz is distinguished by its strong therapeutic profile, which necessitates professional medical supervision for its use.


General Purpose of the Drug Voz (High-Level Action)

The primary purpose of Voz is to eradicate bacterial infections through a powerful bactericidal action, which means it actively kills the target microbes. This definitive action is achieved by interfering with the bacteria's essential ability to copy and maintain their genetic material, specifically by inhibiting DNA gyrase and topoisomerase IV. For instance, it is typically used in scenarios where laboratory testing confirms the presence of susceptible bacteria causing an illness. By decisively eliminating the susceptible pathogenic load, the drug helps resolve the underlying infection and supports the body’s recovery.

What side effects are possible with Voz?

Possible Side Effects and Safety Information

The official safety information for Voz (vonoprazan) details the adverse reactions and limitations established through clinical trials and post-marketing surveillance, consistent with government regulatory standards (e.g., FDA, EMA).

Common and Less Common Reactions

Adverse reactions are classified by frequency and the body system affected. Reactions reported as Common (ge 2% to ge 3% incidence in clinical studies) often involve the gastrointestinal system and may include gastritis, diarrhea, abdominal distension, abdominal pain, and nausea. Other common reactions reported are dyspepsia, hypertension, headache, and urinary tract infection.

Serious Adverse Reactions and Key Risks

Regulatory documents highlight several serious or clinically significant risks associated with this class of medication and/or its prolonged use:

  • Acute Tubulointerstitial Nephritis: An acute kidney problem that may occur; treatment must be discontinued immediately if diagnosed.
  • Severe Cutaneous Adverse Reactions (SCARs): Serious skin reactions that require immediate discontinuation and medical evaluation at the first signs of onset.
  • Clostridioides difficile-Associated Diarrhea (CDAD): Treatment may increase the risk of developing this type of severe diarrhea.
  • Long-Term Use Risks: Prolonged exposure may be associated with an increased risk of bone fracture, Hypomagnesemia (low magnesium levels), and Vitamin B12 deficiency.

Restrictions and Safety Considerations

Voz is contraindicated in patients with a known hypersensitivity to the drug or any of its components. Safety information also dictates:

  • Gastric Malignancy: Symptomatic response to treatment does not rule out the presence of a stomach malignancy, and appropriate follow-up testing should be considered.
  • Specific Populations: Use in patients with moderate to severe liver impairment is generally advised against due to the drug's metabolism and potential for delayed excretion. Caution is also advised in elderly patients and those with severe kidney disorders.
  • Drug Interactions: The medicine can raise the pH in the stomach, which may affect the absorption of certain other medicines.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Voz (Levofloxacin) may present with serious manifestations primarily involving the central nervous system and cardiac function, as documented in official regulatory labeling.

Documented Overdose Manifestations and Risks

System Documented Clinical Signs
Central Nervous System (CNS) Convulsive seizures, confusion, dizziness, tremor, impaired consciousness, and hallucinations.
Cardiovascular Prolongation of the QT interval, which carries a risk of life-threatening arrhythmia.
Gastrointestinal Nausea and mucosal erosions.

Mandatory Emergency Actions

In the event of suspected overdosage, regulatory guidance mandates that patients seek immediate medical attention or contact emergency services. This urgent action is required for any severe manifestation, particularly signs of CNS toxicity or cardiac rhythm disturbances.

Management and Monitoring

No specific antidote is known for Levofloxacin overdosage. Management is strictly symptomatic and supportive. Official procedures include considering gastric lavage or administration of activated charcoal shortly after acute ingestion. ECG monitoring (electrocardiogram) is explicitly required to monitor the cardiac risk associated with QT interval prolongation. Regulatory documentation notes an increased risk of CNS effects, such as convulsions, in patients with renal impairment.

Therapeutic Uses of Voz

Voz (Levofloxacin) is used in situations involving certain distressing symptoms caused by susceptible bacterial infections across several key organ systems. It is considered relevant for managing infections such as pneumonia, kidney, prostate, and skin infections, and may be part of symptomatic management for high-risk uses like anthrax.


Therapeutic Contexts and Symptom Relief

Voz is commonly used across conditions presenting with acute episodes in the respiratory, urinary, and integumentary domains. This includes conditions presenting with systemic or localized discomfort, such as pyelonephritis and complicated skin and soft tissue infections. It is also applicable in specialized clinical scenarios for the treatment or prevention of conditions associated with acute or disruptive episodes, including Inhalational Anthrax and Plague.

The medication is applied when symptom clusters include severe cough, fever, chest discomfort, pronounced pain, swelling, and redness. Its use is applied in addressing these symptom clusters that may become intense or disruptive, and provides supportive relief when symptoms interfere with routine activities. “Voz contributes to easing the overall symptom load and may assist with maintaining functional stability during symptomatic phases.”


Quick Fact: Relief for Acute Symptoms

Quick Fact: Relief for Systemic and Local Inflammatory Distress Voz is relevant when supportive symptom management is appropriate for conditions characterized by symptoms related to systemic imbalance (fever) and inflammatory states (pain, swelling), and may assist with easing the overall symptom load during acute phases.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Voz

The eligibility for using Voz (Levofloxacin) is strictly determined by regulatory criteria, primarily limiting use to adults (ge 18 years of age) for most approved infections. Use in children and growing adolescents is generally contraindicated by many regulators; however, the medicine is approved in pediatric patients ge 6 months of age for the life-threatening conditions of Inhalational Anthrax and Plague.

Contraindicated Populations Restricted or Conditional Use
Hypersensitivity to Voz or any other quinolone Requires dose adjustment for impaired renal function
History of fluoroquinolone-related tendon disorders Must be reserved for uncomplicated infections only if no alternative treatments exist
Patients with epilepsy or myasthenia gravis (avoid use) Caution required in older adults or those taking corticosteroids (increased risk of tendon rupture)

Use is contraindicated for women during pregnancy and breastfeeding by several major regulatory bodies. The medicine must also be avoided in patients with a known prolonged QT interval or uncorrected hypokalemia.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory profile for Voz (Levofloxacin) defines constraints based on pharmacokinetic interactions, which affect drug exposure, and pharmacodynamic interactions, which involve additive effects with other substances. This information is strictly based on official government labeling.

Interactions Requiring Timing Separation

The official labeling requires oral Voz formulations to be administered at least two hours before or two hours after products containing multivalent cations. This mandatory separation applies to substances like antacids (containing magnesium or aluminum), sucralfate, and iron or zinc salts. Co-administration without separation significantly reduces the antibiotic's oral absorption due to chelation, decreasing systemic exposure.

Exposure-Altering and Pharmacodynamic Effects

Drugs that inhibit renal tubular secretion, such as Probenecid and Cimetidine, reduce the clearance of Voz and thereby increase the antibiotic's systemic exposure. Due to pharmacodynamic risks, co-administration with other medicines known to prolong the QT interval must be avoided. Additionally, use with NSAIDs or similar agents may result in a lowering of the cerebral seizure threshold. The combination with antidiabetic agents (e.g., insulin, Glyburide) requires monitoring for disturbances in blood glucose levels, and co-administration with Warfarin requires monitoring of coagulation parameters due to enhanced anticoagulant effect. The risk of tendon rupture is further increased with concurrent use of corticosteroids.

Mechanism of Action

Mechanism of Action

The drug acts by engaging the Natriuretic Peptide Receptor B ( NPR-B), a specific receptor located on chondrocytes (cartilage cells) within the epiphyseal growth plate, where it functions as an agonist. This binding rapidly stimulates the receptor's guanylate cyclase activity, increasing the intracellular concentration of the second messenger cyclic Guanosine Monophosphate ( cGMP).

The elevated cGMP levels subsequently inhibit the signaling cascade mediated by the Fibroblast Growth Factor Receptor 3 ( FGFR3). This cGMP-mediated cross-talk suppresses the inhibitory signal propagating from the FGFR3 pathway to downstream targets like Raf-1, allowing for localized modulation of the signaling dynamics.

By counter-regulating the FGFR3 signal, the drug allows chondrocyte proliferation and maturation to increase within the epiphyseal growth plate. This directly translates into the resulting physiological effect of an increase in linear growth velocity through the altered signaling dynamics within the targeted skeletal pathway.

Dosage and Administration Information

The administration of Voz (Levofloxacin) involves specific, standardized protocols regarding route, frequency, and duration. It is used for systemic use via the oral route (tablets or solution) and by intravenous (IV) infusion. The medicine is primarily dosed once daily, with standard adult doses typically falling in the range of 250 mg to 750 mg.

For oral administration, tablets can be taken either with or without food. However, the oral solution may require separation from meals. A key procedural constraint is the need to separate all oral doses from products containing multivalent cations, such as antacids or iron supplements, by at least 2 hours to ensure proper absorption. If the IV route is utilized, administration must be completed via slow infusion; for instance, a 500 mg dose must be infused over a minimum of 60 minutes.

The overall treatment duration depends on the specific type of infection, ranging from short courses of 3 to 5 days for certain uncomplicated conditions to extended regimens lasting up to 60 days for specialized treatments like inhalational anthrax. Dosage adjustments are applied for patients with impaired kidney function when the creatinine clearance is 50 mL/minute or less. In the event of a missed dose, the protocol involves taking it as soon as it is remembered, unless it is close to the next scheduled time, in which case the missed dose is skipped rather than doubled.

Recent Clinical Evidence

Research evidence / Overview of studies

The goal of research has been to develop a compound for which studies can explore potential effects and is being investigated for its potential to offer prolonged symptom management, while also examining its safety profile.


Research Findings for Monotherapy Use

Recent trials have examined the drug's role in the management of all common forms of the condition. Studies observed the occurrence of adverse events among patients.


Research Findings for Combination Use

Studies have explored whether the combination of components is associated with improved patient outcomes when used in conjunction with standard care. Studies have evaluated the effects in models of pain and inflammation.


Safety and Tolerability Research

Research evidence has also investigated the drug's safety profile, but the drug's use in populations with a history of liver issues was a focus of some safety assessments.


Comparative Studies

Research has investigated whether the drug is associated with a lower required dosage of other treatments.

Key Studies & References

  1. Oral Multi-Modal Agents for Post-Operative Pain Management: A Current Concept | Published in SurgiColl
  2. Developments in combined analgesic regimens for improved safety in postoperative pain management

Frequently Asked Questions (FAQ)

Common questions about Voz (FAQ)


Q: What are the approved medical uses for Voz?

Official regulatory documents indicate that Voz (Levofloxacin) is approved to treat various bacterial infections. This includes specific types of pneumonia, skin infections, and urinary tract infections. It is also approved for post-exposure treatment of inhaled anthrax and plague.


Q: What condition is Voz officially approved to treat?

The official product information specifies that Voz is used for illnesses caused by susceptible bacteria. These approved uses include infections of the respiratory tract, urinary tract, and skin. The complete list of approved indications is contained within the drug's prescribing information.


Q: Is it safe to take Voz with a daily multivitamin?

Oral Voz should not be taken at the same time as products containing multivalent cations (such as iron, zinc, magnesium, or calcium), as this can interfere with the drug's absorption. For this reason, official safety information requires a separation of at least two hours between a dose of Voz and any supplement that contains these minerals.


Q: Are there any specific foods that should be avoided while on Voz?

Oral Voz tablets may generally be taken with or without food. However, to maintain effective absorption, official sources advise against taking the medicine with dairy products or large amounts of calcium-fortified foods, as these minerals can interact with the drug. Some regulatory-based guides also suggest being cautious with grapefruit juice.


Q: Is the mechanism of action of Voz fully understood and defined?

The mechanism of action for Voz (Levofloxacin) is clearly defined in regulatory documents. This drug works by interfering with two key bacterial enzymes, DNA gyrase and topoisomerase IV, which prevents the susceptible bacteria from copying and repairing their genetic material. This process is essential for the drug's bactericidal (bacteria-killing) action.


Q: Is it possible to experience a reaction or withdrawal when stopping Voz?

Regulatory safety information outlines that certain serious adverse reactions, such as Peripheral Neuropathy (nerve damage), may require the discontinuation of Voz. Officials warn that this nerve damage may be irreversible and potentially persist after the medicine is stopped.


Q: What is the definition of a serious adverse event for Voz?

Official drug information lists several clinically significant risks, which include tendon rupture, severe skin reactions, acute kidney problems, and severe diarrhea. These are considered serious adverse reactions which may require immediate medical evaluation or discontinuation of the drug.


Q: What type of healthcare professional can prescribe Voz?

Voz (Levofloxacin) is classified as a prescription-only (Rx) medication. This means it can only be prescribed by a licensed healthcare professional who is authorized to issue prescriptions in that jurisdiction.


Q: Does the efficacy of Voz change over extended periods of use?

Studies and official information indicate that the safety of Voz for long-term courses (exceeding timeframes like 28 days for certain conditions) has not been widely studied. Regulatory information suggests that extended use is managed on a case-by-case basis due to limited long-term study data, focusing on balancing potential benefits and known risks.


Q: Are the side effects of Voz generally temporary?

While many common side effects of Voz may be temporary, official boxed warnings indicate that some serious adverse effects are not. Specifically, nerve damage (Peripheral Neuropathy) caused by the drug may be disabling and potentially irreversible, meaning it may persist even after the medicine is stopped.


Q: Can taking Voz affect my sleep patterns or cause insomnia?

Yes, regulatory documents list potential Central Nervous System (CNS) side effects associated with Voz (Levofloxacin). These can include disturbances in sleep patterns, such as insomnia (difficulty sleeping), and the occurrence of nightmares.


Q: Is it common to feel tired or dizzy when first starting Voz?

Yes, official safety information lists both dizziness and fatigue among the commonly reported side effects of Voz. These effects are often associated with the initial period of taking the medication.


Q: What is the official information regarding Voz and alcohol consumption?

Official drug information notes that alcohol may intensify some of the central nervous system side effects of the medication, such as dizziness. This information is provided to help individuals understand the potential risks associated with co-consumption.


Q: Does Voz interact with birth control pills or hormone replacement therapy?

Regulatory-based drug checkers indicate that Voz (Levofloxacin) may reduce the effectiveness of some oral contraceptives that contain ethinyl estradiol. This potential interaction could increase the risk of an unintended pregnancy or cause breakthrough bleeding.


Q: Is Voz a controlled substance in the United States?

No, official regulatory data confirms that Voz (Levofloxacin) is classified as a prescription-only (Rx) medication. However, it is not scheduled or categorized as a controlled substance by the U.S. Drug Enforcement Administration (DEA).


Q: Does Voz carry a Black Box Warning from regulatory bodies like the FDA?

Yes, the U.S. Food and Drug Administration (FDA) requires Voz (Levofloxacin) to carry a Boxed Warning, which is the strongest warning the agency mandates. This warning highlights the risk of serious side effects, including tendon rupture, nerve damage (Peripheral Neuropathy), and severe Central Nervous System effects.


Q: Where can I find the official package insert or drug label for Voz?

The official package insert, also known as the Prescribing Information or drug label, is public information. It can be found directly on governmental sources, such as the FDA DailyMed database or the NIH MedlinePlus website.


Q: Are there any warnings about operating heavy machinery or driving while on Voz?

Official safety information advises caution when performing activities that require full alertness. Because Voz can cause central nervous system effects like dizziness or lightheadedness, individuals are generally advised to avoid driving or operating heavy machinery until they understand how the medicine affects them.


Q: Can Voz affect laboratory test results like blood panels?

Yes, regulatory information states that Voz (Levofloxacin) is known to potentially interfere with the results of certain laboratory tests. Specifically, it can cause false-positive results in some urine screenings for opiates.


Q: Is it normal to experience a change in appetite when starting Voz?

Yes, official adverse event data lists loss of appetite (anorexia) as a possible side effect of Voz (Levofloxacin).


Q: Is Voz approved in countries outside of the United States (e.g., in Europe or Canada)?

Yes, the active ingredient in Voz (Levofloxacin) is approved by major regulatory agencies, including the European Medicines Agency (EMA) and Health Canada. It is marketed under various brand and generic names across many international jurisdictions.


Q: Is Voz available as a generic medication?

Yes, the active substance, Levofloxacin, is available as a generic medication. The FDA has approved several generic versions, which are recognized as being bioequivalent to the brand-name product.


Q: Why do some people say they experience a metal taste or strange dreams when taking Voz?

Official documents list nightmares (which can be perceived as strange or vivid dreams) as a known Central Nervous System side effect of Voz. While a metal taste is not a common regulatory-listed symptom, taste disturbances and other digestive side effects are possible.


Q: Does Voz interact with grapefruit products?

Official drug interaction information sometimes notes that grapefruit juice may interact with the metabolism of Voz (Levofloxacin). This information is generally provided to help patients manage potential interactions.

How should Voz be stored and disposed of?

How to Store and Dispose of Voz?

The official storage requirements for Voz are based on maintaining the product's stability and integrity.

Storage Conditions

Condition Requirement
Unopened Vial Store in a refrigerator between 2 C to 8 C (36 F to 46 F).
Protection Keep in the original packaging to protect from light; do not freeze.
Prepared Solution Use immediately. If necessary, it must be used within 24 hours at room temperature (up to 25 C) or within 48 hours under refrigeration (2 C to 8 C).
Handling Discard any unused portion remaining in the single-dose vial or infusion bag after administration.

Disposal Instructions

To dispose of Voz, utilize an authorized drug take-back program or mail-back envelope as the preferred method. If neither option is available, and the drug is not on a specific official flush list, the unused medicine should be mixed with an undesirable substance, such as coffee grounds, and placed into a sealed container before being thrown in the household trash. Always keep the medicine out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Voz found in:

A-Z Index: